North America Wound Debridement Products to Grow at 6.9% CAGR

Growing prevalence of chronic ulcers in North America is likely to propel growth of the wound debridement product market in the region significantly in the coming years. In addition, according to the statistics provided by the International Diabetes Federation, there will be over 400 Mn diabetic patients globally, particularly in countries such as Africa, Latin America and Asia. Moreover, nearly 25% of the diabetic patients globally are likely to develop foot ulcers in the coming years. Such factor are likely to propel growth of the wound debridement products market in North America over the coming years.

Leading Segments Impacting Dynamics of the Market

The wound debridement products market in North America is expected to reflect a CAGR of 6.9% over the forecast period, 2016-2024. The chronic ulcer is likely to account for a revenue share of over 45% in the span of next seven years. Whereas, various complications regarding the medical adhesive-related skin injury (MARSI) is likely to inhibit demand for wound debridement products in North America over the coming years. The venous insufficiency ulcers among various chronic wounds accounted for 50% of chronic leg ulcers resulting in venous etiology. In addition, hospitals among various end users are likely to retain dominance in the wound debridement products market in North America in the span of next seven years.

Leading Players Impacting the Market

While there are various techniques for treatment of wound debridement, effective low-frequency ultrasound wound debridement products will be relatively more preferred among the end users. Smith & Nephew PLC, Misonix, Lohmann & Rauscher International and Zimmer Biomet Holdings are likely to lead the market in terms of production of wound debridement products with low frequency ultrasound in the coming years. Whereas, BSN Medical among various companies operating in the wound debridement products market in North America mainly specializes in larva therapy and traditional wound therapy products. Moreover, other key suppliers and manufacturers of wound debridement products in North America include Soring GmbH, DeRoyal Industries Inc. and Arobella Medical LLC.

Impact of Trends and Market Dynamics

Increasing need and preference for removing necrotic tissue, as it could hinder the development and regeneration of new skin has compelled the need to remove dead materials from the skin. Moreover, wounds heal relatively fast, when dead tissues are removed as they could trap bacteria, which could further lead to various infections and odors. Such factors have significantly propelled growth of the wound debridement products market in the coming years.

Moreover, per capita expenditure in healthcare particularly on chronic ulcers is likely to follow an uptrend across various developing and developed countries. Such factors are further likely to fuel demand for products related to wound debridement in North America in the span of next seven years. Furthermore, growing awareness for enhanced application of wound debridement products and advanced wound care management in the home care settings is likely to rev up growth of the wound debridement products market in North America over the coming years.

Growing prevalence of pressure ulcers vary in the range of 0.31% and 0.70% every year in U.S. Additionally, due to growing support by the government in parallel with increase in older population, wound debridement products are likely to witness a significant demand in the coming years. Furthermore, range of wound debridement products include debridement agents and various non-invasive products. Due to availability of range of non-invasive products, wound debridement is likely to witness an upsurge in demand in the coming years. Wound debridement products witness increasing preference among end users in North America. Specialized clinics and ASCs is likely to account for a revenue share of over US$ 100 million by the end of 2024. Sales of wound debridement products for treatment of chronic ulcers across various hospitals in North America is likely to generate major revenues in the coming years. Moreover, the hospitals in North America is likely to reflect an impressive CAGR of 8.2% in the span of next seven years.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12967

Be the first to comment

Leave a Reply

Your email address will not be published.


*